A Preliminary Study of JM-27: A Serum Marker That Can Specifically Identify Men With Symptomatic Benign Prostatic Hyperplasia

Journal of Urology

Volumn 177, Issue 2, 2007, Pages 610-614

  Cannon, Grant W ^a   Mullins, Chris ^b   Lucia, M Scott ^c   Hayward, Simon W ^d   Lin, Victor ^e   Liu, Brian C S ^g   Slawin, Kevin ^f   Rubin, Mark A ^g   Getzenberg, Robert H ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^c Pathology Coordinating Center   (United States)

^d VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^e UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^f BAYLOR COLLEGE OF MEDICINE   (United States)

^g BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

biological markers; immunoassay; prostatic hyperplasia; urinary tract

Indexed keywords

JM 27; MOLECULAR MARKER; UNCLASSIFIED DRUG;

ARTICLE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; QUANTITATIVE ANALYSIS; SENSITIVITY AND SPECIFICITY; SYMPTOMATOLOGY;

ANTIGENS, NEOPLASM; BIOLOGICAL MARKERS; HUMANS; MALE; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; SENSITIVITY AND SPECIFICITY;

EID: 33846157748     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2006.09.023     Document Type: Article

References (12)

1. Oesterling J.E. Benign prostatic hyperplasia: a review of its histogenesis and natural history. Prostate Suppl 6 (1996) 67
2. Thiyagarajan M. alpha-Adrenoceptor antagonists in the treatment of benign prostate hyperplasia. Pharmacology 65 (2002) 119
3. Saigal C.S., and Joyce G. Economic costs of benign prostatic hyperplasia in the private sector. J Urol 173 (2005) 1309
4. Yang Q., Fung K.M., Day W.V., Kropp B.P., and Lin H.K. Androgen receptor signaling is required for androgen-sensitive human prostate cancer cell proliferation and survival. Cancer Cell Int 5 (2005) 8
5. Schwinn D.A., and Michelotti G.A. alpha1-adrenergic receptors in the lower urinary tract and vascular bed: potential role for the alpha1d subtype in filling symptoms and effects of ageing on vascular expression. BJU Int 85 (2000) 6
6. Untergasser G., Madersbacher S., and Berger P. Benign prostatic hyperplasia: age-related tissue-remodeling. Exp Gerontol 40 (2005) 121
7. Prakash K., Pirozzi G., Elashoff M., Munger W., Waga I., Dhir R., et al. Symptomatic and asymptomatic benign prostatic hyperplasia: molecular differentiation by using microarrays. Proc Natl Acad Sci U S A 99 (2002) 7598
8. Shah U.S., Arlotti J., Dhir R., Lu S., Pirozzi G., Prakash K., et al. Androgen regulation of JM-27 is associated with the diseased prostate. J Androl 25 (2004) 618
9. Minnery C.H., and Getzenberg R.H. Benign prostatic hyperplasia cell line viability and modulation of jm-27 by doxazosin and Ibuprofen. J Urol 174 (2005) 375
10. Linton H.J., Marks L.S., Millar L.S., Knott C.L., Rittenhouse H.G., and Mikolajczyk S.D. Benign prostate-specific antigen (BPSA) in serum is increased in benign prostate disease. Clin Chem 49 (2003) 253
11. Gosling J.A., Kung L.S., Dixon J.S., Horan P., Whitbeck C., and Levin R.M. Correlation between the structure and function of the rabbit urinary bladder following partial outlet obstruction. J Urol 163 (2000) 1349
12. Levin R.M., Longhurst P.A., Monson F.C., Kato K., and Wein A.J. Effect of bladder outlet obstruction on the morphology, physiology, and pharmacology of the bladder. Prostate Suppl 3 (1990) 9